BRCA1 and triple-negative breast carcinoma: For hormone-positive patients, inactivating NF1 mutations could be used as the prognostic biomarker of endocrine therapy resistance (5); for patients with triple-negative breast cancer, germline BRCA1/2 mutations could be employed to choose the appropriate medicine.